Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Ring Therapeutics Inc.
Headquarters: Cambridge, MA, United States of America
Website: http://www.ringtx.com
Year Founded: 2017
Status: Private
BioCentury | Sep 19, 2024
Discovery & Translation
Science Spotlight: Cancer prognosis via deep learning, new protein degraders, and more
BioCentury’s roundup of translational innovations
BioCentury | Jun 8, 2023
Management Tracks
New CFO, commercial officer at Pulmocide
Plus: Helmling named CBO at eTheRNA, and updates from EpimAb, Ring, Amarna, XNK and more
BioCentury | May 2, 2023
Management Tracks
Azam named CEO at Inspirna
Plus: Day One promotes Blackman to head of R&D, and updates from Esperovax, Ring, Alladapt, Innoviva and more
BioCentury | Mar 10, 2023
Regulation
March 9 Quick Takes: FDA panel backs Genentech’s Polivy
Plus: QurAlis, Ring raise venture rounds and updates from AZ, BMS and more
BioCentury | Jan 31, 2023
Management Tracks
Baxter’s Accogli named CEO of Chiesi
Plus: J&J CMO Waldstreicher retiring, and updates from the Broad Institute, Ring, Hansa, Vaccitech and Beyond Air
BioCentury | Jul 8, 2022
Discovery & Translation
Ring’s immune-evading anelloviruses; plus Tenaya, Goldfinch and Coagulant
BioCentury’s roundup of translational news
BioCentury | May 27, 2022
Emerging Company Profile
With ProFound, Flagship explores ‘dark proteome’ at the ribosome
The Cambridge-based company emerged from stealth with $75 million
BioCentury | May 6, 2022
Discovery & Translation
Sanofi and ModeX’s Epstein-Barr vaccine; plus San Raffaele, Walden and more
BioCentury’s roundup of translational news
BioCentury | Nov 9, 2021
Management Tracks
Maraganore joins board at Beam
Plus: new CBO, board member at Caribou, Nordic, GT Biopharma and more
BioCentury | Oct 23, 2021
Product Development
Gene therapy’s next class of biotechs
And the innovative technologies they’re developing
Items per page:
1 - 10 of 14